Literature DB >> 12774211

Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging.

M Savoiardo1.   

Abstract

Magnetic resonance imaging (MRI) is not usually considered helpful for establishing the diagnosis of Parkinson's disease, but it is much more important to support the clinical diagnosis in atypical parkinsonian disorders. In multiple system atrophy with predominant parkinsonian features (MSA-P), MRI demonstrates putaminal abnormalities due to loss of neurons and gliosis and accumulation of iron in the posterior lateral part of the nucleus. When cerebellar features are present (MSA-C), pontine and cerebellar atrophy is seen with signal abnormalities that correspond to the distribution of the degenerative changes. In progressive supranuclear palsy, the main abnormality is atrophy of the midbrain. Mild-to-moderate cerebral atrophy may be present, but more-marked asymmetrical atrophy in the posterior frontal and parietal regions contralateral to the side of the clinical manifestations is characteristic of corticobasal degeneration.

Entities:  

Mesh:

Year:  2003        PMID: 12774211     DOI: 10.1007/s100720300036

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  26 in total

1.  Stereotypic behaviors in degenerative dementias.

Authors:  S Prioni; V Fetoni; F Barocco; V Redaelli; C Falcone; P Soliveri; F Tagliavini; A Scaglioni; P Caffarra; L Concari; S Gardini; F Girotti
Journal:  J Neurol       Date:  2012-05-31       Impact factor: 4.849

2.  Hyperintensity of the middle cerebellar peduncles on fluid-attenuated inversion recovery imaging: variation with age and implications for the diagnosis of multiple system atrophy.

Authors:  S Ngai; Y M Tang; L Du; S Stuckey
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

Review 3.  How to diagnose MSA early: the role of magnetic resonance imaging.

Authors:  K Seppi; M F H Schocke; G K Wenning; W Poewe
Journal:  J Neural Transm (Vienna)       Date:  2005-07-06       Impact factor: 3.575

4.  Potential usefulness of signal intensity of cerebral gyri on quantitative susceptibility mapping for discriminating corticobasal degeneration from progressive supranuclear palsy and Parkinson's disease.

Authors:  Mari Miyata; Shingo Kakeda; Yasuko Toyoshima; Satoru Ide; Kazumasa Okada; Hiroaki Adachi; Yi Wang; Yukunori Korogi
Journal:  Neuroradiology       Date:  2019-07-02       Impact factor: 2.804

Review 5.  Other dementias.

Authors:  Gaida Krumina
Journal:  Neuroradiology       Date:  2011-09       Impact factor: 2.804

Review 6.  The role of iron in brain ageing and neurodegenerative disorders.

Authors:  Roberta J Ward; Fabio A Zucca; Jeff H Duyn; Robert R Crichton; Luigi Zecca
Journal:  Lancet Neurol       Date:  2014-10       Impact factor: 44.182

Review 7.  The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 1.

Authors:  T C Booth; M Nathan; A D Waldman; A-M Quigley; A H Schapira; J Buscombe
Journal:  AJNR Am J Neuroradiol       Date:  2014-06-05       Impact factor: 3.825

8.  Ancillary investigations to diagnose parkinsonism: a prospective clinical study.

Authors:  M B Aerts; R A J Esselink; W F Abdo; F J A Meijer; G Drost; N Norgren; M J R Janssen; G F Borm; B R Bloem; M M Verbeek
Journal:  J Neurol       Date:  2014-11-09       Impact factor: 4.849

9.  Differentiation of Parkinsonism-Predominant Multiple System Atrophy from Idiopathic Parkinson Disease Using 3T Susceptibility-Weighted MR Imaging, Focusing on Putaminal Change and Lesion Asymmetry.

Authors:  I Hwang; C-H Sohn; K M Kang; B S Jeon; H-J Kim; S H Choi; T J Yun; J-H Kim
Journal:  AJNR Am J Neuroradiol       Date:  2015-09-03       Impact factor: 3.825

Review 10.  Iron in chronic brain disorders: imaging and neurotherapeutic implications.

Authors:  James Stankiewicz; S Scott Panter; Mohit Neema; Ashish Arora; Courtney E Batt; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.